Financial Performance - Q2 2025 revenue was $47.4 million[21] - Nucleic Acid Production (NAP) revenue was $31.1 million, representing 66% of total revenue[37] - Biologics Safety Testing (BST) revenue was $16.3 million, accounting for 34% of total revenue[37] - The company reported a GAAP net loss of $69.8 million, which includes a $30.4 million non-cash goodwill impairment charge[27] - Adjusted EBITDA was negative $10.4 million, with an adjusted EBITDA margin of -22%[27] - Basic and Diluted EPS were both negative $0.27, while Adjusted EPS was negative $0.08[29] Balance Sheet and Cash Flow - Cash used in operations during Q2 2025 was $10.3 million[33] - The company's cash position is $270 million, with long-term gross debt of $297 million, resulting in net cash of negative $27 million[33] Strategic Initiatives - A restructuring plan is in place, targeting more than $50 million in annual cost savings[15, 39] - The company aims to return to positive adjusted EBITDA in the second half of 2026[15] - The company is targeting positive free cash flow in the second half of 2026[15]

Business Overview - Maravai LifeSciences is targeting high-growth markets in mRNA, gene editing, cell and gene therapy, vaccines and biologics drug manufacturing[6] - The company provides critical assays for detecting impurities during biotherapeutics process development and commercial manufacturing[7] - Nucleic Acid Production accounted for 61% of total revenue in Q1 2025, with revenue of $29 million[19,48] - Biologics Safety Testing accounted for 39% of total revenue in Q1 2025, with revenue of $18 million[41,48] - 96% of top 25 global biopharmaceutical companies ranked by R&D spend are Maravai customers[10,13,14] Financial Highlights - The company's cash position is $285 million as of Q1 2025[51] - Long-term gross debt is $298 million as of Q1 2025[51] - Adjusted EBITDA for Biologics Safety Testing in Q1 2025 was $18 million, representing a 70% adjusted EBITDA margin[48] - Adjusted EBITDA for Nucleic Acid Production in Q1 2025 was ($9 million), representing a (31%) adjusted EBITDA margin[48] - Adjusted net loss was $(20436) thousand, and adjusted fully diluted loss per share was $(008) in Q1 2025[64] Growth and Pipeline - CleanCap® is used in preclinical programs (70% of total programs) and clinical programs (30% of total programs)[28] - Clinical programs using CleanCap® have increased by 15% year-over-year[28]

NASDAQ: MRVI Q1 2025 Financial Results May 12, 2025 Agenda | 01 | Welcome | Deb Hart, Head of Investor Relations | | --- | --- | --- | | 02 | Business Highlights | Trey Martin, Chief Executive Officer | | 03 | Financial Results | Kevin Herde, Chief Financial Officer | | | & Guidance | | | 04 | Q&A Session | Trey Martin, Chief Executive Officer Kevin Herde, Chief Financial Officer | | | | Becky Buzzeo, Chief Commercial Officer | © 2025 Maravai LifeSciences 2 Forward Looking Statements and Use of Non-GAAP Fin ...